Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 5/20 | 0.40 |
| ▸ | MGMT | P16455 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 10/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149200 | 0.88 | SRC (0.43) | MGMTADORA2A | |
| SCHEMBL6133822 | 0.84 | GRM5 (0.41) | SYKAURKBINCENPGRM5MGMT | |
| SCHEMBL5149212 | 0.83 | SRC (0.40) | — | |
| SCHEMBL5152824 | 0.83 | MPO (0.38) | — | |
| SCHEMBL5149185 | 0.83 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5152714 | 0.83 | SRC (0.38) | ADORA2AADORA2B | |
| SCHEMBL5147947 | 0.83 | HRH3 (0.34) | ADORA2AADORA2B | |
| SCHEMBL5150959 | 0.83 | FGFR1 (0.39) | ADORA2A | |
| SCHEMBL5149059 | 0.83 | FGFR2 (0.35) | ADORA2A | |
| SCHEMBL5148946 | 0.83 | SMN1; SMN2 (0.37) | GABRA1GABRG2GABRB3GABRA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1737841-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | Astellas Pharma Inc. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005095384-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF AS ADENOSINE ANTAGONISTS | ASTELLAS PHARMA INC. (JP) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | SYK 1977/4885AURKB 3952/4885INCENP 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.